Literature DB >> 1900241

Growth of Mycobacterium avium in human monocytes: identification of cytokines which reduce and enhance intracellular microbial growth.

M Denis1.   

Abstract

Human monocytes were isolated by standard procedures and their ability to harbor growth of two virulent strains of Mycobacterium avium, TMC724 and TMC7479, was assessed in the absence or presence of cytokines. Both strains of mycobacteria, especially the M. avium TMC7479, grew progressively in untreated human monocytes. Inclusion of certain macrophage-activating cytokines, such as interferon-gamma in the presence of indomethacin or 1.25(OH2)-vitamin D3 (calcitriol) led to significant reductions in bacterial growth at 7 days post-infection. Conversely, treatment of human monocytes with interleukin-(IL) 1, macrophage-colony stimulating factor or IL 3 led to an increased permissiveness of these cells for M. avium. Moreover, these cytokines were shown to increase dramatically extracellular M. avium growth in vitro in tissue culture medium. Further, inclusion of antibodies against IL 1 beta and IL 6 in untreated infected monocytes monolayers led to a reduced growth of M. avium, suggesting that infected monocytes produce factors which enhance their susceptibility to M. avium. Overall, my findings suggest that cytokines may play a bidirectional role in atypical mycobacterial infections, by either increasing or decreasing resistance of the monocyte.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900241     DOI: 10.1002/eji.1830210221

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Altered IL-1 expression and compartmentalization in monocytes from patients with AIDS stimulated with Mycobacterium avium complex.

Authors:  J L Johnson; H Shiratsuchi; Z Toossi; J J Ellner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

Review 2.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

3.  Effects of methylprednisolone on intracellular bacterial growth.

Authors:  G U Meduri; S Kanangat; M Bronze; D R Patterson; C U Meduri; C Pak; E A Tolley; D R Schaberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Striking the right balance; the role of cytokines in mycobacterial disease.

Authors:  C Moreno; A J Rees
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

5.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

Review 6.  Animal and cell-culture models for the study of mycobacterial infections and treatment.

Authors:  I M Orme; A D Roberts; S K Furney; P S Skinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

7.  Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex.

Authors:  K Suzuki; W J Lee; T Hashimoto; E Tanaka; T Murayama; R Amitani; K Yamamoto; F Kuze
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

8.  Envelope glycoprotein (gp120) from HIV-1 enhances Mycobacterium avium growth in human bronchoalveolar macrophages; an effect mediated by enhanced prostaglandin synthesis.

Authors:  M Denis
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

9.  Nonadherent cultures of human monocytes kill Mycobacterium smegmatis, but adherent cultures do not.

Authors:  K Barker; H Fan; C Carroll; G Kaplan; J Barker; W Hellmann; Z A Cohn
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

10.  Effects of cytokines on intracellular growth of Brucella abortus.

Authors:  X Jiang; C L Baldwin
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.